<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3755">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01864564</url>
  </required_header>
  <id_info>
    <org_study_id>F121008004</org_study_id>
    <secondary_id>K12HD001258</secondary_id>
    <nct_id>NCT01864564</nct_id>
  </id_info>
  <brief_title>Early Gestational Diabetes Screening in the Gravid Obese Woman</brief_title>
  <acronym>EGGO</acronym>
  <official_title>Early Gestational Diabetes Screening in the Gravid Obese Woman</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aim 1: To test the hypothesis that early GDM screening between 14-18 weeks in obese&#xD;
      women (body mass index ≥30.0) will result in improved perinatal outcomes.&#xD;
&#xD;
      Specific Aim 2: To test the hypothesis that a lower diagnostic threshold for GDM at 14-18&#xD;
      weeks will result in improved detection of GDM and reduce the need for third-trimester&#xD;
      testing.&#xD;
&#xD;
      Specific Aim 3: To test the hypothesis that 1,5-anhydroglucitol, a sensitive marker of&#xD;
      hyperglycemia, can be used as a simple and sensitive serum test for GDM in the obese&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over 1/3 of reproductive age women are obese. Obese women have higher rates of adverse&#xD;
      pregnancy outcomes, including stillbirth, fetal growth disorders, diabetes, hypertensive&#xD;
      diseases and maternal death. Although weight loss prior to pregnancy is the ideal, a&#xD;
      significant proportion of obese women do not present to care until after conception.&#xD;
      Consequently, developing a comprehensive plan for managing the obese gravida is imperative.&#xD;
      One component of such a plan must include screening and treating for gestational diabetes&#xD;
      (GDM), which is associated with macrosomia, cesarean delivery, preeclampsia, shoulder&#xD;
      dystocia, and neonatal hypoglycemia. Obesity substantially increases the risk of GDM (odds&#xD;
      ratio 2-5). GDM treatment has been shown to improve pregnancy outcomes,but obese women with&#xD;
      GDM continue to have worsened outcomes compared to normal weight women with GDM, with more&#xD;
      cesarean delivery, preeclampsia, macrosomia and stillbirths occurring in obese women. This is&#xD;
      perhaps due to pre-existing insulin resistance in obese women that, when coupled with the&#xD;
      normal insulin resistance of pregnancy, leads to earlier onset of GDM in obese women compared&#xD;
      to normal weight women, with consequently longer fetal exposure to hyperglycemic episodes&#xD;
      prior to diagnosis and treatment.&#xD;
&#xD;
      The American College of Obstetricians and Gynecologists recommends screening obese women for&#xD;
      gestational diabetes (GDM) in the first trimester or upon presentation. However, due to lack&#xD;
      of supporting data, this recommendation is not widely followed and the majority of obese&#xD;
      women do not undergo GDM screening until 24-28 weeks gestation. Postponing testing may delay&#xD;
      the diagnosis and treatment of GDM by 10 weeks or more, resulting in fetal hyperglycemia&#xD;
      during critical periods of fetal growth and development. Early screening, between 14-18 weeks&#xD;
      gestation, in this high-risk population will allow for earlier recognition and treatment of&#xD;
      GDM, thereby improving perinatal outcomes.&#xD;
&#xD;
      Additionally, little is known about screening and diagnostic standards for GDM early in&#xD;
      pregnancy. Currently, when GDM testing is performed early in pregnancy, the criteria used to&#xD;
      diagnose GDM at 24-28 weeks are applied. However, these thresholds were developed for a test&#xD;
      performed at 24-28 weeks; applying these same thresholds at 14-18 weeks may not be&#xD;
      appropriate. As insulin resistance increases throughout pregnancy, lowering the criteria for&#xD;
      glucose tolerance testing earlier in gestation may improve GDM detection and avoid the need&#xD;
      for re-testing later in pregnancy. Alternatively, as GDM is the new-onset of insulin&#xD;
      resistance with resulting hyperglycemia, biomarkers that reflect metabolic markers of recent&#xD;
      hyperglycemic episodes may perform well in screening for GDM and may decrease the patient&#xD;
      burden of, while increasing compliance with, glucose tolerance testing. One such marker that&#xD;
      has been evaluated in Type 2 diabetes is 1,5-anhydroglucitol (AG), an unmetabolized&#xD;
      monosaccharide. AG has a fairly stable steady-state concentration in the blood that is&#xD;
      unaffected by fasting, dietary changes and pregnancy; it is reabsorbed in the renal tubules&#xD;
      by the same transporter that reabsorbs glucose. During a hyperglycemic episode, the presence&#xD;
      of glucose in the urine competitively inhibits the reabsorption of AG, resulting in a&#xD;
      precipitous decline in AG levels. AG levels recover slowly in the presence of continued&#xD;
      hyperglycemia. The rapid fall of AG with the onset of hyperglycemia and its slow recovery in&#xD;
      situations of on-going hyperglycemia suggest it as both a sensitive and specific marker for&#xD;
      new-onset glucose intolerance requiring treatment. As perinatal outcomes are closely linked&#xD;
      to hyperglycemic excursions, (18) AG may be the most sensitive and specific marker for&#xD;
      determining the GDM patient who will benefit most from treatment.&#xD;
&#xD;
      This study is potentially practice changing and could greatly reduce the disparities in&#xD;
      perinatal outcomes seen in obese women. Early GDM screening of obese women may reduce the&#xD;
      risk of cesarean delivery, macrosomia, stillbirth, preterm birth, and preeclampsia in this&#xD;
      population. This study has 3 specific aims:&#xD;
&#xD;
      Specific Aim 1: To test the hypothesis that early GDM screening between 14-18 weeks in obese&#xD;
      women (body mass index ≥30.0) will result in improved composite perinatal outcomes.&#xD;
&#xD;
      Specific Aim 2: To test the hypothesis that a lower diagnostic threshold for GDM at 14-18&#xD;
      weeks will result in improved detection of GDM and reduce the need for third-trimester&#xD;
      testing.&#xD;
&#xD;
      Specific Aim 3: To test the hypothesis that 1,5-anhydroglucitol, a sensitive marker of recent&#xD;
      hyperglycemic excursions, can be used as a simple and sensitive serum test for GDM in the&#xD;
      obese population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 18, 2013</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Composite Perinatal Outcome</measure>
    <time_frame>Baseline to within 6 weeks of delivery</time_frame>
    <description>Any one of the following: Macrosomia (birth weight &gt; 4000 g), primary cesarean, gestational hypertension, preeclampsia, shoulder dystocia, neonatal hyperbilirubinemia, neonatal hypoglycemia (&lt;40 mg/dL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Macrosomia</measure>
    <time_frame>Within 6 weeks of delivery</time_frame>
    <description>Number of infants with Birth weight &gt;4000 g</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Cesarean Delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Primary cesarean : delivery via cesarean, first cesarean (does not include repeat cesarean deliveries)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Induced Hypertension</measure>
    <time_frame>Within 6 weeks of delivery</time_frame>
    <description>Includes gestational hypertension and preeclampsia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shoulder Dystocia</measure>
    <time_frame>At birth</time_frame>
    <description>Shoulder dystocia as identified by delivering physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Hyperbilirubinemia</measure>
    <time_frame>Within 6 weeks of delivery</time_frame>
    <description>serum bilirubin level above the 95th percentile for gestational age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Hypoglycemia</measure>
    <time_frame>Within 6 weeks of delivery</time_frame>
    <description>Blood sugar level &lt;40 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Age at Delivery</measure>
    <time_frame>at delivery</time_frame>
    <description>Gestational age in weeks as calculated by ACOG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Diabetic Medication</measure>
    <time_frame>baseline to delivery</time_frame>
    <description>includes the use of any diabetic medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Medication</measure>
    <time_frame>baseline to delivery</time_frame>
    <description>Includes the use of Insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Large for Gestational Age</measure>
    <time_frame>at delivery</time_frame>
    <description>defined as &gt;= the 90th percentile by Duryea et al</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">962</enrollment>
  <condition>Gestational Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Routine Screening</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early Screening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Early Screen</intervention_name>
    <description>Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
    <arm_group_label>Early Screening</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  18 years and older&#xD;
&#xD;
          -  Body mass index &gt;=30.0&#xD;
&#xD;
          -  &lt;20 weeks gestation at presentation for care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior cesarean&#xD;
&#xD;
          -  History of bariatric surgery&#xD;
&#xD;
          -  Major maternal medical illness (cardiac disease, HIV, hemoglobinopathy, oxygen&#xD;
             requirement)&#xD;
&#xD;
          -  Chronic prednisone use&#xD;
&#xD;
          -  Known fetal anomalies&#xD;
&#xD;
          -  Multifetal gestation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorie M Harper, MD, MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Health System</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <results_first_submitted>April 9, 2020</results_first_submitted>
  <results_first_submitted_qc>June 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2020</results_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Lorie M Harper</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Gestational diabetes</keyword>
  <keyword>Screening</keyword>
  <keyword>Obesity</keyword>
  <keyword>Anhydroglucitol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT01864564/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 17, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT01864564/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Routine Screening</title>
          <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
        </group>
        <group group_id="P2">
          <title>Early Screening</title>
          <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="480"/>
                <participants group_id="P2" count="482"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="443"/>
                <participants group_id="P2" count="387"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not reported</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Routine Screening</title>
          <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
        </group>
        <group group_id="B2">
          <title>Early Screening</title>
          <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="463"/>
            <count group_id="B2" value="459"/>
            <count group_id="B3" value="922"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="5.9"/>
                    <measurement group_id="B2" value="27.2" spread="5.9"/>
                    <measurement group_id="B3" value="27" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <description>All participants were female</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="463"/>
                    <measurement group_id="B2" value="459"/>
                    <measurement group_id="B3" value="922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White, Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black, Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="280"/>
                    <measurement group_id="B3" value="579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="463"/>
                    <measurement group_id="B2" value="459"/>
                    <measurement group_id="B3" value="922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="463"/>
                    <measurement group_id="B2" value="459"/>
                    <measurement group_id="B3" value="922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass index at randomization</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.0" spread="6.5"/>
                    <measurement group_id="B2" value="37.2" spread="6.6"/>
                    <measurement group_id="B3" value="37" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medicaid/no insurance</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="441"/>
                    <measurement group_id="B2" value="434"/>
                    <measurement group_id="B3" value="875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Married</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High School education or greater</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="305"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parous</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="338"/>
                    <measurement group_id="B2" value="329"/>
                    <measurement group_id="B3" value="667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any Smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any alcohol use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any drug use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Depression</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c at 14-20 weeks</title>
          <units>% A1c</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.3" lower_limit="5.0" upper_limit="5.6"/>
                    <measurement group_id="B2" value="5.3" lower_limit="5.0" upper_limit="5.6"/>
                    <measurement group_id="B3" value="5.3" lower_limit="5.0" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age at Randomization</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.6" spread="3.7"/>
                    <measurement group_id="B2" value="13.8" spread="3.8"/>
                    <measurement group_id="B3" value="13.7" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Composite Perinatal Outcome</title>
        <description>Any one of the following: Macrosomia (birth weight &gt; 4000 g), primary cesarean, gestational hypertension, preeclampsia, shoulder dystocia, neonatal hyperbilirubinemia, neonatal hypoglycemia (&lt;40 mg/dL)</description>
        <time_frame>Baseline to within 6 weeks of delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Routine Screening</title>
            <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
          </group>
          <group group_id="O2">
            <title>Early Screening</title>
            <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Composite Perinatal Outcome</title>
          <description>Any one of the following: Macrosomia (birth weight &gt; 4000 g), primary cesarean, gestational hypertension, preeclampsia, shoulder dystocia, neonatal hyperbilirubinemia, neonatal hypoglycemia (&lt;40 mg/dL)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Macrosomia</title>
        <description>Number of infants with Birth weight &gt;4000 g</description>
        <time_frame>Within 6 weeks of delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Routine Screening</title>
            <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
          </group>
          <group group_id="O2">
            <title>Early Screening</title>
            <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Macrosomia</title>
          <description>Number of infants with Birth weight &gt;4000 g</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Cesarean Delivery</title>
        <description>Primary cesarean : delivery via cesarean, first cesarean (does not include repeat cesarean deliveries)</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Routine Screening</title>
            <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
          </group>
          <group group_id="O2">
            <title>Early Screening</title>
            <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Cesarean Delivery</title>
          <description>Primary cesarean : delivery via cesarean, first cesarean (does not include repeat cesarean deliveries)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pregnancy Induced Hypertension</title>
        <description>Includes gestational hypertension and preeclampsia</description>
        <time_frame>Within 6 weeks of delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Routine Screening</title>
            <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
          </group>
          <group group_id="O2">
            <title>Early Screening</title>
            <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Induced Hypertension</title>
          <description>Includes gestational hypertension and preeclampsia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shoulder Dystocia</title>
        <description>Shoulder dystocia as identified by delivering physician</description>
        <time_frame>At birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Routine Screening</title>
            <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
          </group>
          <group group_id="O2">
            <title>Early Screening</title>
            <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Shoulder Dystocia</title>
          <description>Shoulder dystocia as identified by delivering physician</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Hyperbilirubinemia</title>
        <description>serum bilirubin level above the 95th percentile for gestational age</description>
        <time_frame>Within 6 weeks of delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Routine Screening</title>
            <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
          </group>
          <group group_id="O2">
            <title>Early Screening</title>
            <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Hyperbilirubinemia</title>
          <description>serum bilirubin level above the 95th percentile for gestational age</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Hypoglycemia</title>
        <description>Blood sugar level &lt;40 mg/dL</description>
        <time_frame>Within 6 weeks of delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Routine Screening</title>
            <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
          </group>
          <group group_id="O2">
            <title>Early Screening</title>
            <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Hypoglycemia</title>
          <description>Blood sugar level &lt;40 mg/dL</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Age at Delivery</title>
        <description>Gestational age in weeks as calculated by ACOG criteria</description>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Routine Screening</title>
            <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
          </group>
          <group group_id="O2">
            <title>Early Screening</title>
            <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Age at Delivery</title>
          <description>Gestational age in weeks as calculated by ACOG criteria</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" spread="3.4"/>
                    <measurement group_id="O2" value="38.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any Diabetic Medication</title>
        <description>includes the use of any diabetic medication</description>
        <time_frame>baseline to delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Routine Screening</title>
            <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
          </group>
          <group group_id="O2">
            <title>Early Screening</title>
            <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Any Diabetic Medication</title>
          <description>includes the use of any diabetic medication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Medication</title>
        <description>Includes the use of Insulin</description>
        <time_frame>baseline to delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Routine Screening</title>
            <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
          </group>
          <group group_id="O2">
            <title>Early Screening</title>
            <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Medication</title>
          <description>Includes the use of Insulin</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Large for Gestational Age</title>
        <description>defined as &gt;= the 90th percentile by Duryea et al</description>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Routine Screening</title>
            <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
          </group>
          <group group_id="O2">
            <title>Early Screening</title>
            <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Large for Gestational Age</title>
          <description>defined as &gt;= the 90th percentile by Duryea et al</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through 8 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Routine Screening</title>
          <description>Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.</description>
        </group>
        <group group_id="E2">
          <title>Early Screening</title>
          <description>Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.&#xD;
All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation.&#xD;
Early Screen: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Fetal or Neonatal death</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="463"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Other - Preterm Delivery</sub_title>
                <description>Preterm delivery</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Lack of blinding of participants and providers may have introduced bias. The study population being largely Black or Hispanic women and without private insurance limits the generalizability.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lorie M. Harper, MD, MSCI</name_or_title>
      <organization>University of Texas at Austin</organization>
      <phone>512-324-7036</phone>
      <email>lorie.harper@austin.utexas.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

